AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18287373 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding initiated within 1 hour after birth
Number of subjects: 22838
Study 18287373 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding initiated within 24 hours after birth
Number of subjects: 22838
Study 18287373 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially breast-fed infants
Number of subjects: 22838
Study 18287373 — intervention group
Group type: EXPERIMENTAL
Intervention: Late breast-feeding initiation (> 24 hours)
Number of subjects: 22838
Study 18287373 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal initiation of breast-feeding within the first day
Number of subjects: 22838
Study 18287373 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal initiation of breast-feeding within the first hour
Number of subjects: 22838
Study 16005706 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal and non-verbal positive social reinforcement
Number of subjects: 36
Study 16005706 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 36
Study 12446059 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline white blood cell (WBC) count
Number of subjects: 2208
Study 12446059 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) and elevated WBC
Number of subjects: 2208
Study 12446059 — intervention group
Group type: EXPERIMENTAL
Intervention: High C-reactive protein (CRP)
Number of subjects: 2208
Study 10473840 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon technique for measuring exhaled NO
Number of subjects: 16
Study 10473840 — intervention group
Group type: COMPARATOR
Intervention: On-line measurement of exhaled NO
Number of subjects: 16
Study 8934684 — intervention group
Group type: EXPERIMENTAL
Intervention: Difference limen (DL) for discriminating differences in onset time
Number of subjects: 0
Study 8934684 — intervention group
Group type: EXPERIMENTAL
Intervention: Context coding of stimulus information
Number of subjects: 0
Study 1745618 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed graft function (group 1)
Number of subjects: 18
Study 1745618 — intervention group
Group type: COMPARATOR
Intervention: Immediate graft function (group 2)
Number of subjects: 18
Study 6349535 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocardia rubra cell wall skeleton (N-CWS)
Number of subjects: 226
Study 6349535 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocardia rubra cell wall skeleton (N-CWS) and adriamycin
Number of subjects: 226
Study 6349535 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin
Number of subjects: 226
Study 31034260 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Training (HIT)
Number of subjects: 25
Study 29762709 — intervention group
Group type: EXPERIMENTAL
Intervention: KSHV shedding in mothers
Number of subjects: 500
Study 29762709 — intervention group
Group type: EXPERIMENTAL
Intervention: KSHV shedding in children
Number of subjects: 500
Study 29762709 — intervention group
Group type: EXPERIMENTAL
Intervention: EBV shedding in mothers
Number of subjects: 500
Study 29762709 — intervention group
Group type: EXPERIMENTAL
Intervention: EBV shedding in children
Number of subjects: 500
Study 29762709 — intervention group
Group type: EXPERIMENTAL
Intervention: KSHV shedding by sex in children
Number of subjects: 500
Study 29762709 — intervention group
Group type: EXPERIMENTAL
Intervention: KSHV and EBV shedding relationship in mothers
Number of subjects: 500
Study 29762709 — intervention group
Group type: EXPERIMENTAL
Intervention: EBV shedding in children based on KSHV shedding
Number of subjects: 500
Study 29762709 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship between anti-KSHV antibodies and KSHV shedding
Number of subjects: 500
Study 29762709 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship between antimalarial antibodies and KSHV shedding
Number of subjects: 500
Study 29328637 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream containing olive oil squalene
Number of subjects: 76
Study 29328637 — intervention group
Group type: EXPERIMENTAL
Intervention: All active samples (including Alpine Rose stem cells)
Number of subjects: 76
Study 29328637 — intervention group
Group type: EXPERIMENTAL
Intervention: Squalene-containing cream
Number of subjects: 76
Study 24661518 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-up tilt test (HUTT) at 60°, 70°, or 80°
Number of subjects: 107
Study 24661518 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive response to HUTT (n=76)
Number of subjects: 107
Study 24661518 — intervention group
Group type: COMPARATOR
Intervention: Negative response to HUTT (n=31)
Number of subjects: 107
Study 21835514 — intervention group
Group type: COMPARATOR
Intervention: 100% casein (A)
Number of subjects: 15
Study 21835514 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrolysed whey (B)
Number of subjects: 15
Study 21835514 — intervention group
Group type: EXPERIMENTAL
Intervention: amino acids (C)
Number of subjects: 15
Study 21835514 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% casein/60% whey (D)
Number of subjects: 15
Study 19228241 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented training
Number of subjects: 0
Study 19228241 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented rehabilitation
Number of subjects: 0
Study 18525490 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI grading system for cervical intervertebral disc degeneration
Number of subjects: 300
Study 15920716 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff training program (full day seminar + one-hour guidance per month for six months)
Number of subjects: 0
Study 15920716 — intervention group
Group type: COMPARATOR
Intervention: Control group (no staff training)
Number of subjects: 0
Study 15920716 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff training program
Number of subjects: 0
Study 11958495 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient decision aid based on multicriteria decision‐making theory
Number of subjects: 96
Study 11958495 — intervention group
Group type: COMPARATOR
Intervention: Simple educational intervention
Number of subjects: 96
Study 10426236 — intervention group
Group type: EXPERIMENTAL
Intervention: Customised fundal height charts
Number of subjects: 1272
Study 7560143 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive pretraining (written introduction to the group experience)
Number of subjects: 0
Study 7560143 — intervention group
Group type: COMPARATOR
Intervention: Control condition (written information on the history of group psychotherapy)
Number of subjects: 0
Study 2268456 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 0
Study 2268456 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation
Number of subjects: 0
Study 2268456 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported compliance
Number of subjects: 0
Study 7367500 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthetic speech appliance
Number of subjects: 39
Study 7367500 — intervention group
Group type: COMPARATOR
Intervention: Pharyngeal flap surgery
Number of subjects: 39
Study 31377226 — intervention group
Group type: EXPERIMENTAL
Intervention: AQP5 levels in urine (measured in ng/mL)
Number of subjects: 700
Study 31377226 — intervention group
Group type: EXPERIMENTAL
Intervention: AQP5 levels in the highest tertile (16.0 ng/mL)
Number of subjects: 700
Study 31377226 — intervention group
Group type: EXPERIMENTAL
Intervention: AQP5 levels
Number of subjects: 700
Study 30390409 — intervention group
Group type: EXPERIMENTAL
Intervention: CCB + fluvastatin (group B)
Number of subjects: 189
Study 30390409 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (group C)
Number of subjects: 189
Study 30390409 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan + fluvastatin (group D)
Number of subjects: 189
Study 30390409 — intervention group
Group type: COMPARATOR
Intervention: CCBs (group A)
Number of subjects: 189
Study 25077918 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute administration of 8 mg salbutamol
Number of subjects: 20
Study 25077918 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-week administration of 8 mg salbutamol
Number of subjects: 20
Study 25077918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 25193873 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker therapy
Number of subjects: 18254
Study 25193873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18254
Study 22906006 — intervention group
Group type: EXPERIMENTAL
Intervention: VXM01 (oral DNA vaccine)
Number of subjects: 45
Study 22906006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 19967671 — intervention group
Group type: EXPERIMENTAL
Intervention: Burst mode
Number of subjects: 86
Study 19967671 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse mode
Number of subjects: 86
Study 19967671 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear mode
Number of subjects: 86
Study 17606778 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 200 mg daily for fifty days
Number of subjects: 416
Study 17606778 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 500 mg daily for fifty days
Number of subjects: 416
Study 17606778 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 1500 mg daily for fifty days
Number of subjects: 416
Study 17606778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study 15668310 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge care plan intervention as per the Australian Enhanced Primary Care Package
Number of subjects: 189
Study 15668310 — intervention group
Group type: COMPARATOR
Intervention: Existing hospital discharge processes (Control)
Number of subjects: 189
Study 12584670 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 285
Study 12584670 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 285
Study 12584670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 10341162 — intervention group
Group type: EXPERIMENTAL
Intervention: D-tagatose (75 g daily for 8 weeks)
Number of subjects: 16
Study 10341162 — intervention group
Group type: COMPARATOR
Intervention: D-tagatose (75 g single dose)
Number of subjects: 16
Study 10341162 — intervention group
Group type: COMPARATOR
Intervention: Sucrose (25 g with each meal for 8 weeks)
Number of subjects: 16
Study 10341162 — intervention group
Group type: COMPARATOR
Intervention: No sugar supplements (for Type 2 diabetics for 8 weeks)
Number of subjects: 16
Study 7489228 — intervention group
Group type: COMPARATOR
Intervention: Current smokers
Number of subjects: 874
Study 7489228 — intervention group
Group type: COMPARATOR
Intervention: Women consuming fewer than 12 alcoholic drinks in the past 12 months
Number of subjects: 874
Study 7489228 — intervention group
Group type: COMPARATOR
Intervention: Women who never used HRT
Number of subjects: 874
Study 7489228 — intervention group
Group type: COMPARATOR
Intervention: Leisure time physical activity (LTPA) categories
Number of subjects: 874
Study 7489228 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 874
Study 2022861 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyantibiotic cream applied three times daily from the first day of catheterization until bacteriuria was found.
Number of subjects: 747
Study 2022861 — intervention group
Group type: COMPARATOR
Intervention: Routine meatal care with cleansing of the meatal surface during daily bathing (Control).
Number of subjects: 747
Study 7078021 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg of norethindrone acetate and 50 microgram ethinyl estradiol daily for 21 days with 7 days of placebo treatment in each cycle
Number of subjects: 20
Study 7078021 — intervention group
Group type: EXPERIMENTAL
Intervention: One fifth of the hormone dose in form of a continuous daily medication
Number of subjects: 20
Study 7078021 — intervention group
Group type: COMPARATOR
Intervention: Previous use of oral contraceptives
Number of subjects: 20
Study 7078021 — intervention group
Group type: COMPARATOR
Intervention: No previous hormonal contraceptives
Number of subjects: 20
Study 29680218 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Coronary Revascularization (HCR)
Number of subjects: 200
Study 29680218 — intervention group
Group type: COMPARATOR
Intervention: Conventional Coronary Artery Bypass Grafting (CABG)
Number of subjects: 200
Study 27233466 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicidal ideation
Number of subjects: 530
Study 27233466 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of interest
Number of subjects: 530
Study 27233466 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 530
Study 27233466 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychomotor agitation
Number of subjects: 530
Study 27233466 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk behavior
Number of subjects: 530
Study 24635039 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance-enhanced orientation letter
Number of subjects: 0
Study 24635039 — intervention group
Group type: COMPARATOR
Intervention: Orientation letter
Number of subjects: 0
Study 24635039 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 24331802 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV
Number of subjects: 135
Study 24331802 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 135
Study 20499825 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 9031
Study 20499825 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide
Number of subjects: 9031
Study 20499825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9031
Study 18422480 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription omega-3 fatty acid concentrates (P-OM3)
Number of subjects: 0
Study 18422480 — intervention group
Group type: COMPARATOR
Intervention: P-OM3
Number of subjects: 0
Study 16638830 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipido-colloid dressing
Number of subjects: 28
Study 16638830 — intervention group
Group type: COMPARATOR
Intervention: Daily gauze dressing
Number of subjects: 28
Study 14514397 — intervention group
Group type: EXPERIMENTAL
Intervention: F group supplemented orally with enteral nutrient Fresubin 750MCT containing medium (MCT) and long‐chain triglyceride (LCT)
Number of subjects: 30
Study 14514397 — intervention group
Group type: COMPARATOR
Intervention: N group with Nutrition containing only LCT
Number of subjects: 30
Study 10975022 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidamidine HCL (4 mg) taken orally t.i.d. with food
Number of subjects: 50
Study 10975022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 8973430 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP-a mixed with Hib conjugate and i.p.v.
Number of subjects: 120
Study 8973430 — intervention group
Group type: COMPARATOR
Intervention: Separate injections of DTP-a, Hib conjugate, and i.p.v.
Number of subjects: 120
Study 1405620 — intervention group
Group type: EXPERIMENTAL
Intervention: IVH
Number of subjects: 33
Study 1405620 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 33
Study 1405620 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol gallstone group
Number of subjects: 33
Study 6146112 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (30 mg)
Number of subjects: 8
Study 6146112 — intervention group
Group type: EXPERIMENTAL
Intervention: Camazepam (30 mg)
Number of subjects: 8
Study 6146112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31357037 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery rescripting (ImRs) sessions (1-6 sessions until a 35% reduction in symptoms was achieved)
Number of subjects: 13
Study 31357037 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery rescripting (ImRs) sessions
Number of subjects: 13
Study 31357037 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Y-BOCS
Number of subjects: 13
Study 29572795 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and carboplatinum (first-line therapy)
Number of subjects: 104
Study 29572795 — intervention group
Group type: COMPARATOR
Intervention: Cisplatinum-based therapy (including doxorubicin and cyclophosphamide)
Number of subjects: 104
Study 26374836 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressing group (n = 54): povidone-iodine cleaning, mupirocin application, covered with sterile gauze
Number of subjects: 108
Study 26374836 — intervention group
Group type: COMPARATOR
Intervention: Non-dressing group (n = 54): mupirocin application, uncovered exit site
Number of subjects: 108
Study 24519843 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed Decision-Making (IDM) questionnaire
Number of subjects: 99
Study 24519843 — intervention group
Group type: COMPARATOR
Intervention: Doctor's explanation of underlying conditions leading to kidney failure
Number of subjects: 99
Study 24519843 — intervention group
Group type: COMPARATOR
Intervention: Impact of dialysis on daily life
Number of subjects: 99
Study 24519843 — intervention group
Group type: COMPARATOR
Intervention: Life-long need for dialysis
Number of subjects: 99
Study 24519843 — intervention group
Group type: COMPARATOR
Intervention: Doctor's effort to ensure patient understanding
Number of subjects: 99
Study 24519843 — intervention group
Group type: COMPARATOR
Intervention: Decision-making process
Number of subjects: 99
Study 22106842 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive Writing Intervention (EWI)
Number of subjects: 82
Study 22106842 — intervention group
Group type: COMPARATOR
Intervention: Neutral writing control group
Number of subjects: 82
Study 20814785 — intervention group
Group type: COMPARATOR
Intervention: Propofol (200 mcg/kg/min)
Number of subjects: 15
Study 20814785 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (120 mcg/kg/min) plus remifentanil (0.3 mcg/kg/min)
Number of subjects: 15
Study 20814785 — intervention group
Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 15
Study 17507744 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (0.3 g/kg)
Number of subjects: 23
Study 17507744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 16247118 — intervention group
Group type: EXPERIMENTAL
Intervention: Brace only
Number of subjects: 57
Study 16247118 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy only
Number of subjects: 57
Study 16247118 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both (brace and physical therapy)
Number of subjects: 57
Study 12073163 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg L-5-hydroxytryptophan
Number of subjects: 48
Study 12073163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 10097221 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary stenting
Number of subjects: 0
Study 10097221 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation after stenting
Number of subjects: 0
Study 10097221 — intervention group
Group type: COMPARATOR
Intervention: Bailout stenting for failed PTCA
Number of subjects: 0
Study 7749496 — intervention group
Group type: EXPERIMENTAL
Intervention: CV 205‐502 (0.15 mg)
Number of subjects: 12
Study 7749496 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (0.1 mg)
Number of subjects: 12
Study 7749496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7749496 — intervention group
Group type: EXPERIMENTAL
Intervention: CV 205‐502 (0.3 mg/day) - chronic test
Number of subjects: 12
Study 7749496 — intervention group
Group type: EXPERIMENTAL
Intervention: CV 205‐502 (0.6 mg/day) and octreotide (0.6 mg/day) - combined therapy for 3 months
Number of subjects: 12
Study 1645684 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous famotidine (20 mg)
Number of subjects: 13
Study 1645684 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (Control)
Number of subjects: 13
Study 1645684 — intervention group
Group type: COMPARATOR
Intervention: 7% sodium bicarbonate (Control)
Number of subjects: 13
Study 264922 — intervention group
Group type: EXPERIMENTAL
Intervention: alexidine mouthwash (0.035%)
Number of subjects: 207
Study 264922 — intervention group
Group type: COMPARATOR
Intervention: placebo solution
Number of subjects: 207
Study 31168645 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural steroid injections (ESIs)
Number of subjects: 68
Study 29190751 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot-based gel (BG) 100 g containing 12 mmol nitrate
Number of subjects: 12
Study 29190751 — intervention group
Group type: COMPARATOR
Intervention: Nitrate-depleted gel (PLA) 100 g
Number of subjects: 12
Study 24874347 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT group skills training
Number of subjects: 33
Study 24874347 — intervention group
Group type: COMPARATOR
Intervention: Skills handouts
Number of subjects: 33
Study 23286331 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led computer-supported telephone triage
Number of subjects: 3751
Study 23286331 — intervention group
Group type: EXPERIMENTAL
Intervention: GP-led telephone triage
Number of subjects: 3751
Study 23286331 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3751
Study 16717300 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (150 mg/kg mixed in 250 mL of 5% dextrose infused in 20 min, followed by an infusion of 150 mg/kg in 250 mL of 5% dextrose over 24 h)
Number of subjects: 70
Study 16717300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 16717300 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 70
Study 15284686 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenic aspiration
Number of subjects: 50
Study 15284686 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow aspiration
Number of subjects: 50
Study 10625727 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically treated patients with collaterals
Number of subjects: 681
Study 10625727 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgically treated patients with collaterals
Number of subjects: 681
Study 8957921 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer
Number of subjects: 17
Study 8957921 — intervention group
Group type: COMPARATOR
Intervention: Resin composite
Number of subjects: 17